Harness the power of in silico evolution to work for you.
At MAP Bioscience, we focus on providing early-stage drug discovery services to our partners and clients.
- Designing de novo antibodies against selected targets. We design and deliver high-affinity, high-specificity de novo antibodies with high developability, good solubility, low propensity for aggregation, and low propensity for immunogenicity as candidates for further development.
- Humanization. Our proprietary map of human antibody sequence space — built and tested on over a billion antibody sequences — enables us to quickly determine the minimal set of changes we need to make to a sequence for humanization.
- Optimization. We can optimize a starting sequence to “engineer in” desired properties while preserving high affinity for the target.